CIPLA

Cipla Limited is an Indian multinational pharmaceutical and biotechnology company,

headquartered in Mumbai, India; Belgium, & Surrey in the European Union; and Miami,
Florida, in the United States.
Stock price: CIPLA (NSE) Rs. 669.30 +8.65 (+1.31%)
13 Feb, 11:21 am IST - Disclaimer

Founder: Khwaja Abdul Hamied

Founded: 1935
Headquarters: Mumbai, India
PRODUCTS

Active Pharmaceutical Ingredients (API)

Cipla was among the first Indian companies to develop and manufacture Active
Pharmaceutical Ingredients (APIs), the vital raw material for making the drug products. Thus
helping lay the foundation for the pharmaceutical industry in India. Today, we manufacture
over 200 generic APIs. This formidable portfolio covers a broad spectrum of therapeutic
categories, reaching out to over 170 countries around the world. We meet stringent
international standards of quality to deliver API. Thats the Cipla benchmark.

Products and services

Cipla manufactures a range of pharmaceutical and personal care products.[21] The company
offers active pharmaceutical ingredients (APIs); and formulations in therapeutic areas, such
as allergy, analgesic, anti malarial, anti-infectives, cardiology, dermatology and
cosmeceuticals, diabetology, gastroenterology, HIV-AIDS, hormones and steroids, iron
chelators, musculoskeletal, neuropsychiatry, nutritional and ophthalmic products, oncology,
respiratory, urology, and womens health in various dosage forms. It also provides veterinary
products for various animals, including companion, equine, general care, live stock, and
poultry. In addition, the company offers inhaled medication and devices, such as dry powder
inhalers, single-dose capsule and multi-dose dry powder inhalers, breath-actuated metered
dose inhalers, non-static spacers, baby and infant masks, and nasal sprays. Further, it provides
consulting, commissioning, plant engineering, and technical know-how transfer and support
services.[21]
Cipla has over 2000 products in 65 therapeutic categories available in over 40 dosage forms.
[22]
Its key products include the following drugs - Escitalopram (anti-depressant), Lamivudine,
Fluticasone propionate.[2]

HIV/AIDS medication
Cipla is the world's largest manufacturer of antiretroviral drugs[23] (ARVs) to fight
HIV/AIDS, as measured by units produced and distributed. Roughly 40 percent of HIV/AIDS
patients undergoing antiretroviral therapy worldwide take Cipla drugs.[24][25]
From 1972 until 2005 Indian law did not allow product patents on drugs. As a result, Cipla
was able to manufacture medicines which enjoyed patent monopoly in other countries.
Cipla also pioneered a three-in-one tablet called Triomune containing a fixed-dose
combination (FDC) of three ARVs (Lamivudine, stavudine and Nevirapine), something
difficult elsewhere because the three patents were held by different companies. Another

popular fixed-dose combination is produced under the name Duovir-N. This contains
Lamivudine, Zidovudine and Nevirapine. Cipla manufactures generic versions of many of the
most commonly prescribed anti-retroviral medication in the market,[26] and is a highly capable
manufacturer in its own right. This innovation made ARVs far more accessible and easy-totake for patients everywhere, but particularly in poor- and middle-income countries, where
the vast majority of people on anti-retroviral therapy (ART) now take such combination pills.
Cipla was among the first companies to register AIDS drugs under the US relief program
PEPFAR.[27] It has also been a major supplier of ARVs to the Clinton Foundation's HIV/AIDS
Initiative, which has negotiated low-cost drug supplies for numerous developing countries.
Cipla has played an important role in fighting HIV/AIDS in Africa and other developing
countries through its price offers to leading NGOs such as Doctors Without Borders and
Oxfam, and with its keen participation in PEPFAR, the Global Fund, the Clinton Foundation's
HIV/AIDS Initiative.[28]

CIPLA
Type
Traded as

Public
BSE: 500087

NSE: CIPLA
BSE SENSEX Constituent
CNX Nifty Constituent
Industry
Pharmaceuticals
Founded
1935
Founder
Dr. K. A. Hamied
Headquarters
Mumbai, Maharashtra, India
Area served
Worldwide
Y. K. Hamied, Chairman
Key people
Subhanu Saxena (CEO)
Products
Pharmaceuticals and diagnostics
104.83 billion
Revenue
(US$1.6 billion) (2013-14)[1]
18.80 billion
Operating income
(US$300 million) (2012-13)[1]
13.89 billion
Net income
(US$220 million) (2013-14)[1]
109.68 billion
Total assets
(US$1.7 billion) (2013-14)[1]
100.91 billion
Total equity
(US$1.6 billion) (2013-14)[1]
Number of
22,036[2]
employees